Skip to main content

Press Releases View all 20 hits

Cavidi closes US$ 11.5 million financing with Impilo

Cavidi closes US$ 11.5 million financing with Impilo

Press Releases   •   Feb 21, 2018 08:00 GMT

Cavidi announced today a US$ 11.5 million (SEK 90m) investment from Impilo, a leading investment firm focused on Nordic health care companies.

Cavidi Selected to Present at Cavendish Global Health Impact Forum
EIB supports Cavidi’s development of HIV viral load monitoring device
Cavidi introduces Ziva™ – a breakthrough in near-patient viral load monitoring

News View all 42 hits

Cavidi secures ALMI grant to expand presence in US market

Cavidi secures ALMI grant to expand presence in US market

News   •   May 22, 2018 07:56 GMT

Cavidi has been granted matching funds to develop a US market strategy in the research area of viral vectors used to transfect genes in next-generation clinical applications such a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). Applications include quantified potency assessment of viral vectors used in emerging vaccines and gene therapies to treat a wide range of diseases.

Cavidi finalists in Uppsala Innovation Award 2018

Cavidi finalists in Uppsala Innovation Award 2018

News   •   Apr 21, 2018 13:21 GMT

Cavidi were proud to be nominated as a finalist for the Innovation Award for the Uppsala region among all companies. http://foretagargalanuppsala.se/hem/finalister2018/

Innovation success is mission possible at Cavidi

Innovation success is mission possible at Cavidi

News   •   Apr 20, 2018 09:33 GMT

Cavidi an HIV diagnostics industry leader sets sights on virus containment

Cavidi an HIV diagnostics industry leader sets sights on virus containment

News   •   Apr 13, 2018 11:07 GMT

The HIV virus has puzzled scientist around the world for decades. After having remained dormant since its discovery in the 1930's, fifty years later the virus caused one of the worst pandemics the world has seen in modern times. The World Trade Center in Malmö Sweden is home to Cavidi, a medical science company with a mission to contain the spread of this insidious virus known as HIV/AIDS.

Blog posts View all 7 hits

How you can help make viral load testing a reality this World Aids Day
World Aids Day 2013: Halfway to Zero

World Aids Day 2013: Halfway to Zero

Blog posts   •   Nov 28, 2013 09:50 GMT

Each year World Aids Day helps raise awareness around the world. It’s also a time for everyone involved in the fight against HIV to step back and assess our progress. Looking at the HIV community as a whole and Cavidi in particular, I can say it’s been a good year overall. We have seen great progress in the treatment of HIV worldwide.

Could RT technology help close the EID gap?

Blog posts   •   Jul 23, 2012 10:30 GMT

There are around 370,000 new infant infections worldwide each year. A significant number of these children will die if they are not diagnosed early and started on antiretroviral drugs (ARVs). The problem is not the lack of ARVs as much as a lack of proper HIV early infant diagnostics (EID). Recent reports indicate that RT-technology may be an answer to improved access to (EID).

Commentary on ”Reverse Innovation”

Commentary on ”Reverse Innovation”

Blog posts   •   Apr 19, 2012 11:04 GMT

How innovations originating from low-income countries may provide solutions that can help in developed countries.

Images View all 15 hits

Cavidi in Swedish TECH20 - top 2% of start ups

Cavidi in Swedish TECH20 ...

License Creative Commons Attribution
Download
Size

238 KB • 1549 x 1612 px

Cavidi CEO John Reisky de Dubnic presenting at the UN

Cavidi CEO John Reisky de...

The Global Health Impact Forum hosted by the Global Partnerships Forum, Cavendish Global and The New York Academy of Sciences, at the Uni...

License Creative Commons Attribution
Download
Size

106 KB • 357 x 248 px

HIV treatment scale-up and new WHO ARV guidelines 2013

HIV treatment scale-up an...

GENEVA - New HIV treatment guidelines by WHO recommend offering antiretroviral therapy (ART) earlier. Recent evidence indicates that earl...

License Creative Commons Attribution
Download
Size

254 KB • 893 x 600 px

Swedish Ministry of Health presents SWECARE Export Award 2012

Swedish Ministry of Healt...

STOCKHOLM - Swedish Minister for Children and the Elderly, Maria Larsson presents the Export Award to Cavidi CEO, John Reisky de Dubnic (...

License Creative Commons Attribution
Download
Size

1.17 MB • 2007 x 1527 px

Videos 3 hits

Cavidi innovation

Cavidi innovation

Cavidi's innovation is aimed at closing the gap betweenr the market need for Viral Load and current capabilities for decentralised testin...

License Creative Commons Attribution
Download
Size

640 x 360 px

Cavendish Global Health Impact Forum - John Reisky, Cavidi CEO

Cavendish Global Health I...

Cavidi CEO, John Reisky de Dubnic, presents a solution to help close a major treatment gap in the global effort to contain the Human Immu...

License Creative Commons Attribution
Download
Size

88.5 MB • 642 x 360 px

CNN airs segment on Cavidi efforts to expand HIV care accessibility

CNN airs segment on Cavid...

Atlanta – CNN broadcasted a feature piece on Cavidi’s ExaVir Load HIV viral load assay. The story centered on Cavidi’s mission to make es...

License Creative Commons Attribution
Download
Size

4.23 MB • 320 x 240 px

Documents View all 7 hits

Measuring Lentiviral Titers

Measuring Lentiviral Titers

Documents   •   Jan 28, 2016 08:17 GMT

The second in a series of whitepapers covering the importance of accurate viral titer measurement when using viral vectors in experiments for research, drug development, and bioprocessing. Experimental results and comparisons for accuracy.

Viral Titer Counts

Viral Titer Counts

Documents   •   Jan 28, 2016 08:12 GMT

First in a series of whitepapers on the subject of measuring viral titer when using viral stocks. The methods available and the one chosen can have an impact on experimental outcomes and accuracy.

MSF report on the development needs in HIV viral load monitoring access

Routine use of viral load testing makes business sense: it will save money on drugs with effective monitoring of patients. MSF identifies the needs of a solution in a wish list on p23. This is the market opportunity that Cavidi is seeking to address with our new platform meeting requirements that MSF have identified for laboratory-based tests. Cavidi ref on p 5,20,21,23,30,and 31.

Cavidi Corporate Brochure

Cavidi Corporate Brochure

Documents   •   Nov 01, 2012 13:46 GMT

Contacts 1 hit

  • Press Contact
  • Corporate Communications
  • anfgdrxgewsi.ozrldcufietelcbd@ybcakvvidzdizl.saxemp
  • +46(0)702798454